Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients
Haemophilia2016Vol. 23(1), pp. 25–32
Citations Over TimeTop 10% of 2016 papers
Abstract
rpFVIII showed good haemostatic efficacy with no recurrences in most cases, with consumption substantially less than in the registration study. Treatment decisions were based on FVIII activity levels and clinical assessment. The ability to titrate rpFVIII dose using FVIII activity was considered advantageous compared with BPA therapy. Notable delays in diagnosis were observed.
Related Papers
- → Genetic causes of haemophilia in women and girls(2020)64 cited
- → Inhibitors in the Swedish population with severe haemophilia A and B: a 20‐year survey(2002)32 cited
- → Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey(2002)28 cited
- → Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates(1999)16 cited
- → Genetic-Epidemiologic Study of Haemophilia A and B in Hungary(1990)9 cited